JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia
Tóm tắt
Background: JAK2V617F mutation occurs in 90% of polycythemia vera (PV) and in 50% of essential thrombocythemia (ET) patients. Materials and methods: 253 consecutive patients affected by myeloproliferative disorders (MPD, 121 PV, 132 ET) were evaluated and stratified in 4 age groups: 18–39, 40–59, 60–75 and over 75 years (>75). The JAK2V617F mutation was searched and its allele burden was evaluated. Results: The percentage of mutated patients increased progressively with age mainly in patients >75 (p=0.0015 vs 18–39, p=0.0021 vs 40–59 and p=0.012 vs 60–75). We also found a progressive increase in allele burden with age (R2=0.042). Thrombotic events were more common in patients carrying the mutation in comparison with wild type (WT) (p=0.006, coefficient risk 1.94). No differences in the percentage of patients carrying the JAK2V617F mutation were found, in spite of different follow-up durations (<5 yrs, 5–10 yrs, 10–15 yrs, >15 yrs). The JAK2V617F allele burden was similar in patients with (57±31%) and without (45±26%) long-term hydroxyurea treatment. Conclusions: JAK2V617F mutation is more common in old than in young patients with MPD. Older patients have an higher allele burden.
Tài liệu tham khảo
Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913–6.
Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916–8.
Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–97.
Baxter EJ, Scott LM, Campbell PJ et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–61.
Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation in JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–90.
James C, Ugo V, Le Couedec JP et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–8.
Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788–92.
Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–68.
Campbell P, Scott LM, Buck G et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2V617F mutation status: a prospective study. Lancet 2005; 366: 1945–53.
Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556–62.
Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–6.
Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera and essential thrombocythemia. Blood 2007; 110: 840–6.
Lansdorp PM. Telomers, stem cells and hematology. Blood 2008; 111: 1759–66.
Alzarez-Larran A, Cervantes F, Bellosillo B et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218–23.
Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocytemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial. Br J Haematol 2000; 110: 577–83.
Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic bcr/abl-negative myeloproliferative disorders. Leukemia 2008; 22: 905–14.
Berlin N. Diagnosis and classification of polycythemias. Semin Hematol 1978; 12: 339–51.
Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39.
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 292–302.
Passamonti F, Rumi E, Pietra D et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34 cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–82.
Lussana F, Cabrelon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Associations of V167FJak2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systemic review. Thromb Res 2009; 124: 409–17.
Antonioli E; Guglielmelli P, Pancrazi A et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–9.
Teofili L, Giona F, Martini M et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007; 110: 3384–6.
Tefferi A, Thiele J, Orazi A et al. Proposal and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–7.
Lippert E, Boissinot M, Kralovics R et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865–7.
Beer PA, Campbell PJ, Scott LM et al. MPL mutation in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141–9.
Girodon F, Schaeffer C, Cleyrat C et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V671Fpositive patients within the first years of hydroxyurea therapy. Haematologica 2008; 93: 1723–7.